β3-adrenoceptor agonists: Potential, pitfalls and progress

European Journal of Pharmacology

Volumn 440, Issue 2-3, 2002, Pages 99-107

  Arch, Jonathan R S ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF BUCKINGHAM   (United Kingdom)

Author keywords

3 Adrenoceptor; 3 Adrenoceptor agonist; 4 Adrenoceptor; Diabetes; Obesity; Thermogenesis

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 [1 [2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYLAMINO]CYCLOPENTYLMETHYL]PHENOXYMETHYLPHENYLPHOSPHONIC ACID; 4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]PROPYL]BENZOIC ACID; 4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]PROPYL]BENZOIC ACID METHYL ESTER HYDROGEN MALEATE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID METHYL ESTER; 5 [2 [2 (3,4 DIHYDROXYPHENYL) 2 HYDROXYETHYLAMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLATE; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; 6 [4 [2 [2 HYDROXY 3 (2 OXO 2,3 DIHYDRO 1H BENZOIMIDAZOL 4 YLOXY)PROPYLAMINO] 2 METHYLPROPYL]PHENOXY]NICOTINAMIDE; 6 [4 [2 [[3 (9H CARBAZOL 4 YLOXY) 2 HYDROXYPROPYL]AMINO] 2 METHYLPROPYL]PHENOXY] 3 PYRIDINECARBOXAMIDE; AD 9677; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 4 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CYANOPINDOLOL; CYCLIC AMP; CYCLOHEXYL[4 [2 [2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYLAMINO]ETHYL]PHENOXYMETHYL]PHOSPHINIC ACID; GR 265261 X; INSULIN; ISOPRENALINE; L 478337; L 748328; L 755507; L 796568; LY 362884; LY 377604; N [4 [2 (2 HYDROXY 2 PYRIDIN 3 YLETHYLAMINO)ETHYL]PHENYL] 4 [4 (4 TRIFLUOROMETHYLPHENYL)THIAZOL 2 YL]BENZENESULFONAMIDE; N [4 [2 [[3 [3 (ACETAMIDOMETHYL)PHENOXY] 2 HYDROXYPROPYL]AMINO]ETHYL]PHENYL]BENZENESULFONAMIDE; N [4 [2 [[3 [3 (AMINOSULFONYL)PHENOXY] 2 HYDROXYPROPYL]AMINO]ETHYL]PHENYL]BENZENESULFONAMIDE; NORADRENALIN; PROTEIN KINASE C; RNA; SB 220646; SB 251023; SULFONAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BROWN ADIPOSE TISSUE; CELL MEMBRANE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; ENERGY BALANCE; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; INSULIN SENSITIVITY; LIPID OXIDATION; MONKEY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR AFFINITY; SKELETAL MUSCLE; SPECIES DIFFERENCE; THERMOGENESIS; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE;

ADRENERGIC BETA-AGONISTS; ANIMALS; ANTI-OBESITY AGENTS; BODY WEIGHT; DIOXOLES; ENERGY METABOLISM; ETHANOLAMINES; HUMANS; OBESITY; RECEPTORS, ADRENERGIC, BETA-3;

EID: 0037066575     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)01421-8     Document Type: Article

References (78)

1. The effect of a novel β-agonist BRL 26830A on weight and protein loss in obese patients
2. 3-adrenergic receptor with body mass index
3. 3-adrenceptor
4. 3-adrenergic agonists
5. Reduction of obesity in mice with a novel type of thermogenic β-adrenergic agonist
6. 3 and atypical β-adrenoceptors
7. Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs
8. Treatment of obesity with thermogenic β-adrenoceptor agonists: Studies on BRL 26830A in rodents
9. Influences on body composition and mechanism of action of the β-adrenoceptor agonist BRL 26830A
10. 3-adrenoceptor agonist in human right atrial appendage and human white adipocytes
11. Contribution of BAT and skeletal muscle to thermogenesis induced by ephedrine in man
12. Chronic administration of BRL 26830A for 9 weeks improves insulin sensitivity but does not prevent weight gain in gold-thioglucose obese mice
13. 3-adrenergic receptor antagonists
14. Effects of novel β-adrenoceptor agonists on carbohydrate metabolism: Relevance for the treatment of non-insulin dependent diabetes
15. BRL 35135, a potent and selective atypical β-adrenoceptor agonist
16. 3-adrenoceptor studies using a monoclonal antibody
17. The effects of a new β-adrenoceptor agonist BRL 26830A in refractory obesity
18. Anti-obesity drugs: A critical review of current therapies and future opportunities
19. Binding, gating and efficacy
20. Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical β adrenoceptor agonist
21. 3-Adrenergic agonists: Potential therapeutics for obesity
22. Factors influencing the composition of the weight lost by obese patients on a reducing diet
23. 3-adrenergic receptor
24. 3 adrenergic receptor agonist increases metabolic rate in Rhesus monkeys
25. Nonshivering thermogenesis in the rat: II. Measurements of blood flow with microspheres point to brown adipose tissue as the dominant site of the calorigenesis induced by noradrenaline
26. 3-adrenergic receptor gene with body mass index
27. 4-adrenoceptor
28. 3-adrenoceptors
29. Primates in the experimental pharmacology of obesity
30. Studies on the relation between mobilization of free fatty acids and energy metabolism in man: Effects of norepinephrine and nicotinic acid
31. 3-adrenoceptor agonists on lipolysis in human omental adipocytes
32. 3-adrenoceptor gene forms a well-conserved haplotype that is associated with moderate obesity and altered receptor function
33. Protein kinase C activation: Isozyme-specific effects on metabolism and cardiovascular complications in diabetes
34. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle
35. Mice expressing human but not murine β-adrenergic receptors under the control of human gene regulatory elements
36. 3-adrenoceptor agonist, in genetically obese diabetic mice
37. Four β-adrenoceptor subtypes in the mammalian heart
38. 3-adrenoceptor in the rat
39. 4-adrenoceptor pharmacology
40. The relative contribution of affinity and efficacy to agonist activity: Organ selectivity of noradrenaline and oxymetazoline with reference to the classification of drug receptor
41. y
42. A risk-benefit assessment of anti-obesity drugs
43. 4-adrenoceptor mediated responses occur in parallel in a rat model of cardiac failure
44. 3-adrenergic-independent effects of CGP 12177 in brown adipose tissue
45. 1-adrenergic receptors
46. 3-adrenoceptors in rat white adipose tissues by radioligand binding assay
47. 3-adrenoceptor agonist (CL 316,243)
48. 3-adrenoceptor agonist, in obese men
49. Muscle lipid accumulation and protein kinase C activation in the insulin-resistant chronically glucose-infused rat
50. 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans
51. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue
52. 3-selective antagonists, aryloxypropanolaminotetralins
53. 3 adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl))ethyl]amino]phenyl]-4-[4-[4- (trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide
54. Phenethanolamine derivatives with calorigenic and antidiabetic qualities
55. 1/2-antagonist properties, in healthy male subjects
56. 3-adrenergic receptors
57. Chronotropic response to (±)-CGP12177 in right atria of stressed rats
58. 1 adrenoceptor-mediated thermogenesis in man
59. 3-adrenergic stimulation of human thermogenesis and lipid use
60. 3-adrenoceptor agonists of differing selectivities
61. 3 Receptor agonists for the treatment of obesity
62. BRL 35135: An orally active antihyperglycaemic agent with weight reducing effects
63. 4'-adrenoreceptor and other atypical β-adrenoreceptors
64. 3-adrenoceptor
65. Differences between the effects of noradrenaline and the β-adrenoceptor agonist BRL 28410 in brown adipose tissue and hind limb of the anaesthetized rat
66. 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima fatty rats - Induction of uncoupling protein and activation of glucose transporter 4 in white fat
67. 3-adrenoceptor agonist in human omental adipocytes
68. 3-adrenoceptor agonist, in obese men
69. 3-adrenoceptor agonists as antiobesity and antidiabetes drugs in humans: Current status and future prospects
70. 3-adrenoceptor agonist in humans
71. 3-adrenoceptors mediate metabolic responses to isoprenaline
72. 3 agonist SR58611A
73. 3-adrenoceptor depends on receptor expression level and nature of the assay
74. Thermogenesis and weight control
75. Anti-obesity activity of a novel β-adrenoceptor agonist (BRL 26830A) in diet-restricted obese subjects